All storiesCancer

USC Scientists Develop Method to Continuously Produce Cancer-Fighting Immune Cells

Researchers at USC have created a system that may enable a renewable supply of genetically engineered immune cells to fight cancer by modifying immature immune cells to continuously produce tumor-targeting cells.

NeoMD Editors · 2026-10-17 · 02:38 AM EDT

For information, not personal medical advice. Discuss treatment decisions with a qualified clinician.

The quick read

Key takeaways

USC scientists developed a technique modifying immature immune cells to continuously produce cancer-fighting cells within the body, differing from traditional methods that modify mature cells externally.
Current findings are based on laboratory research with no available data on animal or human testing, leaving safety, effectiveness, and patient benefit unconfirmed.
If proven safe and effective, this approach could improve cancer immunotherapy by overcoming limitations in existing therapies that rely on mature immune cells.

Editorial illustration for USC Scientists Develop Method to Continuously Produce Cancer-Fighting Immune Cells — AI-generated editorial illustration.

Scientists at the University of Southern California (USC) have developed a novel approach to generate a potentially never-ending supply of immune cells engineered to fight cancer. Their technique focuses on modifying immature immune cells, rather than mature ones, to enable continuous production of tumor-fighting cells inside the body.

What the Researchers Found

The USC team discovered that by growing and genetically altering immature immune cells, it is possible to establish a system that can keep producing cancer-targeting immune cells over time. This method contrasts with previous approaches that modify mature immune cells outside the body and then infuse them into patients, where their number and duration of activity can be limited.

Evidence and Limitations

Supporting editorial illustration for USC Scientists Develop Method to Continuously Produce Cancer-Fighting Immune Cells — AI-generated editorial illustration.

The information available comes from laboratory research on immune cells and genetic engineering techniques. Details about whether this approach has been tested in animals or humans were not provided. It is important to note that while the strategy shows promise in creating a renewable immune response against tumors, there is no current data confirming patient benefit, safety, or effectiveness in clinical settings.

Therefore, the findings are preliminary and mainly in the research phase. The ability to produce a continuous supply of immune cells could potentially improve cancer immunotherapy, but significant further testing is needed.

Potential Implications

If future studies demonstrate safety and effectiveness, this method might lead to treatments that provide long-lasting immune support against cancer by overcoming the limitations seen with current cell-based therapies that use mature immune cells. However, no approved therapies currently exist based on this technology, and it remains an area of active investigation.

Source: ScienceDaily Medical